Key result
Prophylactic amiodarone or sotalol cuts POAF but fails to reduce length of stay or costs.
Why the study?
Although prophylactic drug therapy reduces postoperative AF frequency after cardiac surgery, its impact on length of stay and hospital costs remains unclear.
Does prophylactic drug therapy against atrial fibrillation reduce length of stay or hospital costs in patients after cardiac surgery?
Systematic Review
Does prophylactic drug therapy against atrial fibrillation reduce length of stay or hospital costs in patients after cardiac surgery?
While prophylactic amiodarone or sotalol reduces the frequency of postoperative atrial fibrillation after cardiac surgery, there is little evidence that it provides an economic advantage by reducing length of stay or hospital costs.
No takes yet. Share an insight, caveat, or question.
Reduces POAF without consistent LOS or cost savings; challenges assumption that arrhythmia prevention alone improves resource use.
A 2001 study conducted a systematic review in Atrial fibrillation after cardiac surgery. Prophylactic amiodarone or sotalol was evaluated on Length of stay and hospital cost. Prophylactic amiodarone or sotalol significantly reduced postoperative atrial fibrillation in 5 of 7 studies, but reduced length of stay and hospital costs in only 1 study.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: